SHENZHEN, China, Dec. 4, 2025 /PRNewswire/ -- The first phase (300 MW/1200 MWh) of China's largest electrochemical energy storage station, powered by SINEXCEL's 1725kW utility-scale Power Conversion System (PCS), has been successfully commissioned. This milestone marks a critical step toward full-capacity operation and will significantly enhance grid stability and accelerate clean-energy adoption.
This site is one of the two project locations of China's largest electrochemical energy storage station - 600MW/2400MWh. It includes 240 battery containers and 60 units of prefabricated cabin. Once the entire project is complete, it will form an integrated "wind–solar–thermal–storage–transmission" model that maximizes renewable-energy utilization and enhances overall system flexibility.
SINEXCEL (300693.SZ) supplied 60 prefabricated cabins equipped with 180 units of its 1725kW PCS for this project. Delivering peak efficiency of up to 98.5%, the PCS employs advanced multi-string technology for enhanced battery protection and supports flexible configurations of 1, 2, 4, or 8 battery strings. Its combined AC/DC output simplifies system control and future expansion, while IP54-rated cabinets ensure reliable outdoor operation. With a rapid 10 ms response time for real-time grid balancing, the product meets major compliance standards across North America, Europe, Australia, Japan and China.
With a global footprint spanning 40+ countries and over 5,000 deployments worldwide, SINEXCEL has installed over 12GW of storage capacity, delivering solutions for utility-scale, C&I, and microgrid applications.
The successful participation in these landmark projects underscore SINEXCEL's technical strength and ongoing commitment to enabling a more resilient and sustainable energy future.
About SINEXCEL
Founded in 2007, SINEXCEL is a pioneer in energy storage, EV charging and power quality solutions. With 12 GW of installed storage, 140,000 EV chargers and nearly 20 million amperes of AHF deployed, SINEXCEL partners with industry leaders like EVE Energy and Schneider Electric to empower energy freedom.
Contact:
melody_yu@sinexcel.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
300MW/1200MWh Energy Storage Station Successfully Commissioned -- Powered by SINEXCEL's 1725kW PCS
|
New kit offers researchers and development teams a meaningful advance in expression speed and output
BOSTON, May 13, 2026 /PRNewswire/ -- GenScript Biotech Corporation announced the launch of TurboCHO™ Protein Expression Kit, a next-generation antibody expression reagent designed to set a new benchmark for speed, performance, output and ease-of-use. One of the company's largest global product launches to date, this kit targets the fast-growing expression reagent market, driven by high-throughput and AI-enabled research.
Producing research-grade antibodies and proteins is a foundational step in drug discovery and biologics development. The new kit brings GenScript's proven protein-expression technology directly to the bench in a ready-to-use format, enabling labs of any size to generate high‑quality protein in as little as five business days. As a result, researchers can access reliable data sooner and make earlier, more confident decisions.
"TurboCHO™ Protein Expression Kit delivers outstanding performance and unmatched value, putting powerful innovation within reach of every lab working to advance science," said GenScript's Rotating CEO Sherry Shao. "By providing a launchpad to market, this kit helps bring new medicines to patients' faster, when time matters most."
The product debuted yesterday at the opening of the PEGS Summit in Boston, but attendees will have opportunities throughout the week to learn more and engage with the GenScript team. The Protein Expression Kit is available in two configurations:
- Pro: Delivers high-yield protein expression in as little as 5 business days, designed for easy integration into existing workflows.
- Prime (Licensed): Enhanced performance for teams seeking maximum speed, with results as early as Day 3 and even higher yields.
Early Feedback Supports Real-World Impact
Early adopters in the beta program have reported performance that is "best in class" for speed and value, demonstrating its real-world impact.
_________________________________________________________________________________
Performance Snapshot: How the Kit Compares
- Redefines expression speed, providing Day 5 yields (or Day 3 for Prime) comparable to competitor Day 10 results, substantially shortening timelines and accelerating decision-making
- Delivers higher yields with lower reagent input, improving overall cost efficiency and throughput
- Produces up to three-fold higher yield(or 5-fold for Prime) after Protein A purification versus other market solutions
- Features a proprietary high‑performing cell line and optimized transfection system
_________________________________________________________________________________
For drug developers and research teams managing increasingly compressed discovery timelines, this performance translates into faster candidate selection, reduced time-to-data, and the capacity to validate more candidates as they move into experimental testing.
The launch represents the first phase of a broader innovation roadmap designed to drive continued industry leadership, with planned advances spanning next‑generation CHO cell line enhancements, improved transfection systems, and scalable, automation‑ready formats.
"By delivering higher-quality antibody expression with dramatically faster time-to-data, we are eliminating a critical bottleneck in drug discovery," said Ray Chen, President of GenScript Life Science Group. "Designed for today's complex molecules, this kit ensures reproducibility and seamless screen-to-scale translation, while enabling more designs to be tested at lower cost. For research teams working under aggressive discovery timelines, the real question isn't whether to adopt this solution. It's how quickly they choose to leverage it to redefine what's possible."
TurboCHO™ Protein Expression Kit is available immediately through GenScript's direct sales channels and authorized distributors. To support early adoption, GenScript is offering introductory pricing for a limited time, along with technical support for onboarding and workflow optimization. Inventory is in place to support both domestic and international demand. For more information or pricing, visit the GenScript website.
About GenScript
Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. As a cornerstone of the global life science ecosystem, GenScript actively collaborates with a diverse network of partners—from academic institutions to industry leaders—to co-create cutting-edge solutions that redefine service excellence. Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript has become a trusted global partner with a team of 6,100+ employees, supporting over 200,000 customers across 100+ countries and regions, including the world's Top 20 pharma companies. For more information: www.genscript.com
Media Contacts:
Kate Grusich
Senior Corporate Communications Manager
Katherina.Grusich@genscript.com
New kit offers researchers and development teams a meaningful advance in expression speed and output
BOSTON, May 13, 2026 /PRNewswire/ -- GenScript Biotech Corporation announced the launch of TurboCHO™ Protein Expression Kit, a next-generation antibody expression reagent designed to set a new benchmark for speed, performance, output and ease-of-use. One of the company's largest global product launches to date, this kit targets the fast-growing expression reagent market, driven by high-throughput and AI-enabled research.
Producing research-grade antibodies and proteins is a foundational step in drug discovery and biologics development. The new kit brings GenScript's proven protein-expression technology directly to the bench in a ready-to-use format, enabling labs of any size to generate high‑quality protein in as little as five business days. As a result, researchers can access reliable data sooner and make earlier, more confident decisions.
"TurboCHO™ Protein Expression Kit delivers outstanding performance and unmatched value, putting powerful innovation within reach of every lab working to advance science," said GenScript's Rotating CEO Sherry Shao. "By providing a launchpad to market, this kit helps bring new medicines to patients' faster, when time matters most."
The product debuted yesterday at the opening of the PEGS Summit in Boston, but attendees will have opportunities throughout the week to learn more and engage with the GenScript team. The Protein Expression Kit is available in two configurations:
- Pro: Delivers high-yield protein expression in as little as 5 business days, designed for easy integration into existing workflows.
- Prime (Licensed): Enhanced performance for teams seeking maximum speed, with results as early as Day 3 and even higher yields.
Early Feedback Supports Real-World Impact
Early adopters in the beta program have reported performance that is "best in class" for speed and value, demonstrating its real-world impact.
_________________________________________________________________________________
Performance Snapshot: How the Kit Compares
- Redefines expression speed, providing Day 5 yields (or Day 3 for Prime) comparable to competitor Day 10 results, substantially shortening timelines and accelerating decision-making
- Delivers higher yields with lower reagent input, improving overall cost efficiency and throughput
- Produces up to three-fold higher yield(or 5-fold for Prime) after Protein A purification versus other market solutions
- Features a proprietary high‑performing cell line and optimized transfection system
_________________________________________________________________________________
For drug developers and research teams managing increasingly compressed discovery timelines, this performance translates into faster candidate selection, reduced time-to-data, and the capacity to validate more candidates as they move into experimental testing.
The launch represents the first phase of a broader innovation roadmap designed to drive continued industry leadership, with planned advances spanning next‑generation CHO cell line enhancements, improved transfection systems, and scalable, automation‑ready formats.
"By delivering higher-quality antibody expression with dramatically faster time-to-data, we are eliminating a critical bottleneck in drug discovery," said Ray Chen, President of GenScript Life Science Group. "Designed for today's complex molecules, this kit ensures reproducibility and seamless screen-to-scale translation, while enabling more designs to be tested at lower cost. For research teams working under aggressive discovery timelines, the real question isn't whether to adopt this solution. It's how quickly they choose to leverage it to redefine what's possible."
TurboCHO™ Protein Expression Kit is available immediately through GenScript's direct sales channels and authorized distributors. To support early adoption, GenScript is offering introductory pricing for a limited time, along with technical support for onboarding and workflow optimization. Inventory is in place to support both domestic and international demand. For more information or pricing, visit the GenScript website.
About GenScript
Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. As a cornerstone of the global life science ecosystem, GenScript actively collaborates with a diverse network of partners—from academic institutions to industry leaders—to co-create cutting-edge solutions that redefine service excellence. Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript has become a trusted global partner with a team of 6,100+ employees, supporting over 200,000 customers across 100+ countries and regions, including the world's Top 20 pharma companies. For more information: www.genscript.com
Media Contacts:
Kate Grusich
Senior Corporate Communications Manager
Katherina.Grusich@genscript.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
GenScript Launches TurboCHO™ Protein Expression Kit, Delivering the Fastest Path to Antibodies in its Class
GenScript Launches TurboCHO™ Protein Expression Kit, Delivering the Fastest Path to Antibodies in its Class
